Benitec Biopharma (BNTC) Total Non-Current Liabilities (2025)
Benitec Biopharma (BNTC) reported Total Non-Current Liabilities of $3.3 million for Q4 2025, up 44.54% sequentially from $2.3 million in Q2 2025.
Benitec Biopharma (BNTC) Total Non-Current Liabilities (2025) Analysis & Trends
Benitec Biopharma (BNTC) has 1 years of Total Non-Current Liabilities data on file, last reported at $3.3 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities changed N/A year-over-year to $3.3 million; the trailing twelve-month figure through Dec 2025 stood at $3.3 million (changed N/A YoY), and the FY2025 full-year result was $2.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities rose to $3.3 million in Q4 2025, from $2.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $3.3 million in Q4 2025 to a low of $2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Benitec Biopharma | 46.45 Mn | 46.45 Mn | - | 3.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.32 Mn |
| Jun 30, 2025 | 2.30 Mn |